Genomic Molecular Tumour Board (MTB) for lung cancer (pilot) EQA 2024

This EQA is aimed at teams interpreting genomic data for lung cancer (tissue testing).

 

EQA participation will be expected from the whole genomic multidisciplinary team. Participants may prefer to create a new user account for this team which is separate from their genomics laboratory EQA account (please contact GenQA for further information) as it is the MTB process which will be assessed, not solely the laboratory’s activity and not solely the clinician’s activity.

 

EQA procedure

This pilot aims to assess the MTB process and has been split into three stages:

 

• Part 1: MTB preparation

Information prepared in advance for discussion at the MTB meeting. This would be in your usual local format which could be the clinical report which is produced and any research on the variants of interest identified.  A referral card containing clinical information will be provided. The results of genomic testing will also be provided.

 

• Part 2: MTB discussions

Information recorded during the MTB discussion. This could be added to your preparation document or could be a separate standalone form or document or a screenshot of your electronic MTB system.

 

• Part 3: MTB outcome

The outcome of the MTB, this information will be collected by GenQA as a form and any pertinent documents which would be your usual method of recording outcomes may be uploaded.

 

Results submission

MTB preparation and follow-up can be submitted as a dedicated form, presentation, screenshot, or document submitted as a pdf file. Report submission would be in your usual laboratory format. Any documents submitted should be anonymised.

 

Distribution date

The EQA will be distributed in October 2024 and 8 weeks will be allowed for results submission.